| Biomarker ID | 934 |
| PMID | 22640805 |
| Year | 2012 |
| Biomarker | NACA + CCNB1 |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | CCNB1 upregulated in Prostate cancer; NACA Downregulated in Prostate Cancer |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways include (CCNB1): T cell receptor regulation of apoptosis, Cell cycle, Oncostatin M, Chk1/Chk2(Cds1)-mediated inactivation of cyclin B-Cdk1 complex, p53 signaling pathway |
| Experiment | BPC VS BP |
| Type of Biomarker | Diagnostic |
| Cohort | Confirmation Set: 37 PCas and 36 unmatched benign prostates containing PCa (BPCs) and were contrasted with 28 benign prostates (BPs) from patients free of PCa. Validation Set: independent set of 51 BPCs and BPs (GSE17951) |
| Senstivity | NA |
| Specificity | NA |
| AUC | Training: 0.836; Validation: 0.897 |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | quantitative real time polymerase chain reactions (qRT-PCR) |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on Independent Patient Cohort |
| Technical Name | NACA, CCNB1 |